NO311785B1 - Anvendelse av et legemiddel med vasodilaterende aktivitet for fremstilling av et medikament for å forbedre seksualrespons hos etmenneske - Google Patents

Anvendelse av et legemiddel med vasodilaterende aktivitet for fremstilling av et medikament for å forbedre seksualrespons hos etmenneske Download PDF

Info

Publication number: NO311785B1
Authority: NO; Norway
Prior art keywords: drug; administration; patients; erectile; response
Prior art date: 1993-08-13

Application number

NO19960549A

Other languages

English (en)

Norwegian (no)

Other versions

NO960549D0 (no

NO960549L (no

Inventor

Adrian W Zorgniotti

Diane-Marie Gioco

Original Assignee

Zonagen Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-08-13

Filing date

1996-02-12

Publication date

2002-01-28

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22311403&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO311785(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1996-02-12 Application filed by Zonagen Inc filed Critical Zonagen Inc

1996-02-12 Publication of NO960549D0 publication Critical patent/NO960549D0/no

1996-04-12 Publication of NO960549L publication Critical patent/NO960549L/no

2002-01-28 Publication of NO311785B1 publication Critical patent/NO311785B1/no

Links

230000036332 sexual response Effects 0.000 title claims abstract description 35
241000282414 Homo sapiens Species 0.000 title claims abstract description 17
239000003814 drug Substances 0.000 title claims description 67
229940079593 drug Drugs 0.000 title claims description 64
230000000304 vasodilatating effect Effects 0.000 title claims description 26
238000004519 manufacturing process Methods 0.000 title claims description 4
PPWLAQVKIFDULF-UHFFFAOYSA-N 2-phenyl-1h-pyrrolo[2,3-b]pyridine Chemical compound N1C2=NC=CC=C2C=C1C1=CC=CC=C1 PPWLAQVKIFDULF-UHFFFAOYSA-N 0.000 claims description 39
201000001881 impotence Diseases 0.000 claims description 39
229960003056 phentolamine mesylate Drugs 0.000 claims description 39
XQYZDYMELSJDRZ-UHFFFAOYSA-N papaverine Chemical compound C1=C(OC)C(OC)=CC=C1CC1=NC=CC2=CC(OC)=C(OC)C=C12 XQYZDYMELSJDRZ-UHFFFAOYSA-N 0.000 claims description 20
229960001999 phentolamine Drugs 0.000 claims description 16
MRBDMNSDAVCSSF-UHFFFAOYSA-N phentolamine Chemical compound C1=CC(C)=CC=C1N(C=1C=C(O)C=CC=1)CC1=NCCN1 MRBDMNSDAVCSSF-UHFFFAOYSA-N 0.000 claims description 16
238000011282 treatment Methods 0.000 claims description 16
229930008281 A03AD01 - Papaverine Natural products 0.000 claims description 9
229960001789 papaverine Drugs 0.000 claims description 9
BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 claims description 8
BMUKKTUHUDJSNZ-UHFFFAOYSA-N 4-[1-hydroxy-2-(1-phenoxypropan-2-ylamino)propyl]phenol Chemical compound C=1C=C(O)C=CC=1C(O)C(C)NC(C)COC1=CC=CC=C1 BMUKKTUHUDJSNZ-UHFFFAOYSA-N 0.000 claims description 7
QZVCTJOXCFMACW-UHFFFAOYSA-N Phenoxybenzamine Chemical compound C=1C=CC=CC=1CN(CCCl)C(C)COC1=CC=CC=C1 QZVCTJOXCFMACW-UHFFFAOYSA-N 0.000 claims description 7
229960004801 imipramine Drugs 0.000 claims description 7
229960004819 isoxsuprine Drugs 0.000 claims description 7
229960003418 phenoxybenzamine Drugs 0.000 claims description 7
SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 claims description 6
VRYMTAVOXVTQEF-UHFFFAOYSA-N acetic acid [4-[2-(dimethylamino)ethoxy]-2-methyl-5-propan-2-ylphenyl] ester Chemical compound CC(C)C1=CC(OC(C)=O)=C(C)C=C1OCCN(C)C VRYMTAVOXVTQEF-UHFFFAOYSA-N 0.000 claims description 6
229960003509 moxisylyte Drugs 0.000 claims description 6
238000002360 preparation method Methods 0.000 claims description 6
229960001722 verapamil Drugs 0.000 claims description 6
SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 claims description 5
239000000006 Nitroglycerin Substances 0.000 claims description 5
BLGXFZZNTVWLAY-CCZXDCJGSA-N Yohimbine Natural products C1=CC=C2C(CCN3C[C@@H]4CC[C@@H](O)[C@H]([C@H]4C[C@H]33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-CCZXDCJGSA-N 0.000 claims description 5
BLGXFZZNTVWLAY-UHFFFAOYSA-N beta-Yohimbin Natural products C1=CC=C2C(CCN3CC4CCC(O)C(C4CC33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-UHFFFAOYSA-N 0.000 claims description 5
229960003711 glyceryl trinitrate Drugs 0.000 claims description 5
229960002312 tolazoline Drugs 0.000 claims description 5
JIVZKJJQOZQXQB-UHFFFAOYSA-N tolazoline Chemical compound C=1C=CC=CC=1CC1=NCCN1 JIVZKJJQOZQXQB-UHFFFAOYSA-N 0.000 claims description 5
229960000317 yohimbine Drugs 0.000 claims description 5
BLGXFZZNTVWLAY-SCYLSFHTSA-N yohimbine Chemical compound C1=CC=C2C(CCN3C[C@@H]4CC[C@H](O)[C@@H]([C@H]4C[C@H]33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-SCYLSFHTSA-N 0.000 claims description 5
AADVZSXPNRLYLV-UHFFFAOYSA-N yohimbine carboxylic acid Natural products C1=CC=C2C(CCN3CC4CCC(C(C4CC33)C(O)=O)O)=C3NC2=C1 AADVZSXPNRLYLV-UHFFFAOYSA-N 0.000 claims description 5
KBAFPSLPKGSANY-UHFFFAOYSA-N Naftidrofuryl Chemical compound C=1C=CC2=CC=CC=C2C=1CC(C(=O)OCCN(CC)CC)CC1CCCO1 KBAFPSLPKGSANY-UHFFFAOYSA-N 0.000 claims description 4
229960001132 naftidrofuryl Drugs 0.000 claims description 4
239000003071 vasodilator agent Substances 0.000 abstract description 41
238000000034 method Methods 0.000 abstract description 38
230000000694 effects Effects 0.000 abstract description 20
229940124549 vasodilator Drugs 0.000 abstract description 17
230000004087 circulation Effects 0.000 abstract description 6
230000001856 erectile effect Effects 0.000 description 43
210000001367 artery Anatomy 0.000 description 27
230000004044 response Effects 0.000 description 26
230000017531 blood circulation Effects 0.000 description 18
208000010228 Erectile Dysfunction Diseases 0.000 description 17
230000035515 penetration Effects 0.000 description 16
239000003795 chemical substances by application Substances 0.000 description 13
230000001568 sexual effect Effects 0.000 description 13
210000005226 corpus cavernosum Anatomy 0.000 description 12
239000003826 tablet Substances 0.000 description 12
210000004392 genitalia Anatomy 0.000 description 11
230000002792 vascular Effects 0.000 description 11
229940068196 placebo Drugs 0.000 description 10
239000000902 placebo Substances 0.000 description 10
239000002550 vasoactive agent Substances 0.000 description 10
210000003899 penis Anatomy 0.000 description 9
230000000638 stimulation Effects 0.000 description 9
239000000150 Sympathomimetic Substances 0.000 description 7
206010054880 Vascular insufficiency Diseases 0.000 description 7
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
239000007924 injection Substances 0.000 description 7
238000002347 injection Methods 0.000 description 7
239000007926 intracavernous injection Substances 0.000 description 7
208000023577 vascular insufficiency disease Diseases 0.000 description 7
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
-1 sodium nitroferricyanide Chemical compound 0.000 description 6
230000037007 arousal Effects 0.000 description 5
239000008280 blood Substances 0.000 description 5
210000004369 blood Anatomy 0.000 description 5
210000003029 clitoris Anatomy 0.000 description 5
201000010099 disease Diseases 0.000 description 5
230000003993 interaction Effects 0.000 description 5
239000010410 layer Substances 0.000 description 5
238000012360 testing method Methods 0.000 description 5
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 4
238000010521 absorption reaction Methods 0.000 description 4
230000009471 action Effects 0.000 description 4
239000002160 alpha blocker Substances 0.000 description 4
RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 4
230000002124 endocrine Effects 0.000 description 4
210000005225 erectile tissue Anatomy 0.000 description 4
238000009472 formulation Methods 0.000 description 4
210000003090 iliac artery Anatomy 0.000 description 4
230000006872 improvement Effects 0.000 description 4
230000001965 increasing effect Effects 0.000 description 4
239000000203 mixture Substances 0.000 description 4
229940082615 organic nitrates used in cardiac disease Drugs 0.000 description 4
230000008961 swelling Effects 0.000 description 4
210000001215 vagina Anatomy 0.000 description 4
MVQVNTPHUGQQHK-UHFFFAOYSA-N 3-pyridinemethanol Chemical compound OCC1=CC=CN=C1 MVQVNTPHUGQQHK-UHFFFAOYSA-N 0.000 description 3
241001313288 Labia Species 0.000 description 3
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
206010052005 Psychogenic erectile dysfunction Diseases 0.000 description 3
230000002159 abnormal effect Effects 0.000 description 3
239000000853 adhesive Substances 0.000 description 3
230000001070 adhesive effect Effects 0.000 description 3
230000008321 arterial blood flow Effects 0.000 description 3
230000008859 change Effects 0.000 description 3
208000014674 injury Diseases 0.000 description 3
239000008101 lactose Substances 0.000 description 3
210000004185 liver Anatomy 0.000 description 3
210000000214 mouth Anatomy 0.000 description 3
239000007922 nasal spray Substances 0.000 description 3
229960004738 nicotinyl alcohol Drugs 0.000 description 3
239000002674 ointment Substances 0.000 description 3
230000001107 psychogenic effect Effects 0.000 description 3
210000002460 smooth muscle Anatomy 0.000 description 3
239000000050 smooth muscle relaxant Substances 0.000 description 3
230000009885 systemic effect Effects 0.000 description 3
230000008733 trauma Effects 0.000 description 3
238000002604 ultrasonography Methods 0.000 description 3
208000000331 vasculogenic impotence Diseases 0.000 description 3
UOTMYNBWXDUBNX-UHFFFAOYSA-N 1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxyisoquinolin-2-ium;chloride Chemical compound Cl.C1=C(OC)C(OC)=CC=C1CC1=NC=CC2=CC(OC)=C(OC)C=C12 UOTMYNBWXDUBNX-UHFFFAOYSA-N 0.000 description 2
QHZLMUACJMDIAE-UHFFFAOYSA-N 1-monopalmitoylglycerol Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)CO QHZLMUACJMDIAE-UHFFFAOYSA-N 0.000 description 2
VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
RPTUSVTUFVMDQK-UHFFFAOYSA-N Hidralazin Chemical compound C1=CC=C2C(NN)=NN=CC2=C1 RPTUSVTUFVMDQK-UHFFFAOYSA-N 0.000 description 2
241000282412 Homo Species 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
OWYWGLHRNBIFJP-UHFFFAOYSA-N Ipazine Chemical compound CCN(CC)C1=NC(Cl)=NC(NC(C)C)=N1 OWYWGLHRNBIFJP-UHFFFAOYSA-N 0.000 description 2
LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 2
206010028980 Neoplasm Diseases 0.000 description 2
229920002367 Polyisobutene Polymers 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
239000000674 adrenergic antagonist Substances 0.000 description 2
150000001412 amines Chemical class 0.000 description 2
HSNWZBCBUUSSQD-UHFFFAOYSA-N amyl nitrate Chemical compound CCCCCO[N+]([O-])=O HSNWZBCBUUSSQD-UHFFFAOYSA-N 0.000 description 2
230000001623 arteriogenic effect Effects 0.000 description 2
210000003403 autonomic nervous system Anatomy 0.000 description 2
239000011230 binding agent Substances 0.000 description 2
229960001948 caffeine Drugs 0.000 description 2
VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 2
239000000969 carrier Substances 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
230000008602 contraction Effects 0.000 description 2
230000007423 decrease Effects 0.000 description 2
206010012601 diabetes mellitus Diseases 0.000 description 2
238000003745 diagnosis Methods 0.000 description 2
210000002249 digestive system Anatomy 0.000 description 2
208000035475 disorder Diseases 0.000 description 2
210000003238 esophagus Anatomy 0.000 description 2
230000003176 fibrotic effect Effects 0.000 description 2
238000010579 first pass effect Methods 0.000 description 2
239000012530 fluid Substances 0.000 description 2
PIPZGJSEDRMUAW-VJDCAHTMSA-N hydron;methyl (1s,15r,18s,19r,20s)-18-hydroxy-1,3,11,12,14,15,16,17,18,19,20,21-dodecahydroyohimban-19-carboxylate;chloride Chemical compound Cl.C1=CC=C2C(CCN3C[C@@H]4CC[C@H](O)[C@@H]([C@H]4C[C@H]33)C(=O)OC)=C3NC2=C1 PIPZGJSEDRMUAW-VJDCAHTMSA-N 0.000 description 2
230000001771 impaired effect Effects 0.000 description 2
230000001939 inductive effect Effects 0.000 description 2
230000000977 initiatory effect Effects 0.000 description 2
238000011835 investigation Methods 0.000 description 2
230000003902 lesion Effects 0.000 description 2
235000011475 lollipops Nutrition 0.000 description 2
238000005461 lubrication Methods 0.000 description 2
239000000463 material Substances 0.000 description 2
238000005259 measurement Methods 0.000 description 2
210000004379 membrane Anatomy 0.000 description 2
239000012528 membrane Substances 0.000 description 2
239000002480 mineral oil Substances 0.000 description 2
235000010446 mineral oil Nutrition 0.000 description 2
210000004400 mucous membrane Anatomy 0.000 description 2
210000002464 muscle smooth vascular Anatomy 0.000 description 2
229940097496 nasal spray Drugs 0.000 description 2
230000001272 neurogenic effect Effects 0.000 description 2
229960003512 nicotinic acid Drugs 0.000 description 2
235000001968 nicotinic acid Nutrition 0.000 description 2
239000011664 nicotinic acid Substances 0.000 description 2
229960003207 papaverine hydrochloride Drugs 0.000 description 2
230000000144 pharmacologic effect Effects 0.000 description 2
229920000728 polyester Polymers 0.000 description 2
210000003240 portal vein Anatomy 0.000 description 2
230000033904 relaxation of vascular smooth muscle Effects 0.000 description 2
230000035807 sensation Effects 0.000 description 2
239000000243 solution Substances 0.000 description 2
210000002784 stomach Anatomy 0.000 description 2
239000000829 suppository Substances 0.000 description 2
230000001975 sympathomimetic effect Effects 0.000 description 2
230000035488 systolic blood pressure Effects 0.000 description 2
238000001931 thermography Methods 0.000 description 2
230000037317 transdermal delivery Effects 0.000 description 2
210000005166 vasculature Anatomy 0.000 description 2
230000002227 vasoactive effect Effects 0.000 description 2
238000000827 velocimetry Methods 0.000 description 2
206010067484 Adverse reaction Diseases 0.000 description 1
206010002383 Angina Pectoris Diseases 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
206010061666 Autonomic neuropathy Diseases 0.000 description 1
229940127291 Calcium channel antagonist Drugs 0.000 description 1
208000034656 Contusions Diseases 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
208000016192 Demyelinating disease Diseases 0.000 description 1
206010012305 Demyelination Diseases 0.000 description 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
208000021663 Female sexual arousal disease Diseases 0.000 description 1
206010016654 Fibrosis Diseases 0.000 description 1
108700012941 GNRH1 Proteins 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 1
206010018691 Granuloma Diseases 0.000 description 1
206010058359 Hypogonadism Diseases 0.000 description 1
QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
239000004166 Lanolin Substances 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
206010049816 Muscle tightness Diseases 0.000 description 1
206010028735 Nasal congestion Diseases 0.000 description 1
CLJHABUMMDMAFA-UHFFFAOYSA-N Nylidrin hydrochloride Chemical compound [Cl-].C=1C=C(O)C=CC=1C(O)C(C)[NH2+]C(C)CCC1=CC=CC=C1 CLJHABUMMDMAFA-UHFFFAOYSA-N 0.000 description 1
101800000989 Oxytocin Proteins 0.000 description 1
XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 description 1
102100031951 Oxytocin-neurophysin 1 Human genes 0.000 description 1
208000002193 Pain Diseases 0.000 description 1
206010056303 Painful erection Diseases 0.000 description 1
206010033892 Paraplegia Diseases 0.000 description 1
206010061336 Pelvic neoplasm Diseases 0.000 description 1
208000004362 Penile Induration Diseases 0.000 description 1
208000020758 Peyronie disease Diseases 0.000 description 1
208000007913 Pituitary Neoplasms Diseases 0.000 description 1
201000005746 Pituitary adenoma Diseases 0.000 description 1
206010061538 Pituitary tumour benign Diseases 0.000 description 1
239000004743 Polypropylene Substances 0.000 description 1
208000006262 Psychological Sexual Dysfunctions Diseases 0.000 description 1
241000700159 Rattus Species 0.000 description 1
201000001880 Sexual dysfunction Diseases 0.000 description 1
208000006011 Stroke Diseases 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
206010047141 Vasodilatation Diseases 0.000 description 1
206010047700 Vomiting Diseases 0.000 description 1
DOQPXTMNIUCOSY-UHFFFAOYSA-N [4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl]-[2-(3,4-dimethoxyphenyl)ethyl]-methylazanium;chloride Chemical compound [H+].[Cl-].C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 DOQPXTMNIUCOSY-UHFFFAOYSA-N 0.000 description 1
210000001015 abdomen Anatomy 0.000 description 1
230000005856 abnormality Effects 0.000 description 1
NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
239000012790 adhesive layer Substances 0.000 description 1
230000006838 adverse reaction Effects 0.000 description 1
239000000556 agonist Substances 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
210000003484 anatomy Anatomy 0.000 description 1
239000002220 antihypertensive agent Substances 0.000 description 1
229940030600 antihypertensive agent Drugs 0.000 description 1
239000003420 antiserotonin agent Substances 0.000 description 1
210000000702 aorta abdominal Anatomy 0.000 description 1
238000013459 approach Methods 0.000 description 1
235000010385 ascorbyl palmitate Nutrition 0.000 description 1
210000001142 back Anatomy 0.000 description 1
230000006399 behavior Effects 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
230000008901 benefit Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
239000002981 blocking agent Substances 0.000 description 1
230000008499 blood brain barrier function Effects 0.000 description 1
230000036772 blood pressure Effects 0.000 description 1
210000004204 blood vessel Anatomy 0.000 description 1
210000001218 blood-brain barrier Anatomy 0.000 description 1
230000037396 body weight Effects 0.000 description 1
239000000480 calcium channel blocker Substances 0.000 description 1
239000002371 cardiac agent Substances 0.000 description 1
239000000496 cardiotonic agent Substances 0.000 description 1
230000009084 cardiovascular function Effects 0.000 description 1
150000003943 catecholamines Chemical class 0.000 description 1
210000003169 central nervous system Anatomy 0.000 description 1
210000003679 cervix uteri Anatomy 0.000 description 1
229940112822 chewing gum Drugs 0.000 description 1
235000015218 chewing gum Nutrition 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
208000020832 chronic kidney disease Diseases 0.000 description 1
208000022831 chronic renal failure syndrome Diseases 0.000 description 1
230000007882 cirrhosis Effects 0.000 description 1
208000019425 cirrhosis of liver Diseases 0.000 description 1
229940110456 cocoa butter Drugs 0.000 description 1
235000019868 cocoa butter Nutrition 0.000 description 1
238000007906 compression Methods 0.000 description 1
230000006835 compression Effects 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
238000012937 correction Methods 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
239000003431 cross linking reagent Substances 0.000 description 1
108700027018 deaminooxytocin Proteins 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000001934 delay Effects 0.000 description 1
238000002716 delivery method Methods 0.000 description 1
GTYWGUNQAMYZPF-QPLNMOKZSA-N demoxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSCCC(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 GTYWGUNQAMYZPF-QPLNMOKZSA-N 0.000 description 1
229960000477 demoxytocin Drugs 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
238000009792 diffusion process Methods 0.000 description 1
208000002173 dizziness Diseases 0.000 description 1
238000001647 drug administration Methods 0.000 description 1
230000000857 drug effect Effects 0.000 description 1
230000004064 dysfunction Effects 0.000 description 1
230000002526 effect on cardiovascular system Effects 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
210000000750 endocrine system Anatomy 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
206010015037 epilepsy Diseases 0.000 description 1
230000009986 erectile function Effects 0.000 description 1
229940011871 estrogen Drugs 0.000 description 1
239000000262 estrogen Substances 0.000 description 1
230000005281 excited state Effects 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
210000001752 female genitalia Anatomy 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
210000003953 foreskin Anatomy 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
230000002710 gonadal effect Effects 0.000 description 1
230000002440 hepatic effect Effects 0.000 description 1
230000003054 hormonal effect Effects 0.000 description 1
229960002474 hydralazine Drugs 0.000 description 1
235000019866 hydrogenated palm kernel oil Nutrition 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
208000031424 hyperprolactinemia Diseases 0.000 description 1
230000002989 hypothyroidism Effects 0.000 description 1
208000003532 hypothyroidism Diseases 0.000 description 1
XZZXIYZZBJDEEP-UHFFFAOYSA-N imipramine hydrochloride Chemical compound [Cl-].C1CC2=CC=CC=C2N(CCC[NH+](C)C)C2=CC=CC=C21 XZZXIYZZBJDEEP-UHFFFAOYSA-N 0.000 description 1
229960002102 imipramine hydrochloride Drugs 0.000 description 1
230000002779 inactivation Effects 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
210000000936 intestine Anatomy 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
229940039717 lanolin Drugs 0.000 description 1
235000019388 lanolin Nutrition 0.000 description 1
230000002045 lasting effect Effects 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
230000003908 liver function Effects 0.000 description 1
239000007937 lozenge Substances 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
210000000260 male genitalia Anatomy 0.000 description 1
230000003211 malignant effect Effects 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
210000002200 mouth mucosa Anatomy 0.000 description 1
210000004877 mucosa Anatomy 0.000 description 1
230000004118 muscle contraction Effects 0.000 description 1
230000000926 neurological effect Effects 0.000 description 1
210000002445 nipple Anatomy 0.000 description 1
XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 description 1
229960001723 oxytocin Drugs 0.000 description 1
230000000149 penetrating effect Effects 0.000 description 1
230000018052 penile erection Effects 0.000 description 1
210000000578 peripheral nerve Anatomy 0.000 description 1
210000001428 peripheral nervous system Anatomy 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
229940124531 pharmaceutical excipient Drugs 0.000 description 1
210000003800 pharynx Anatomy 0.000 description 1
238000013186 photoplethysmography Methods 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
208000021310 pituitary gland adenoma Diseases 0.000 description 1
239000004033 plastic Substances 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
229920006267 polyester film Polymers 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
229920001155 polypropylene Polymers 0.000 description 1
201000011264 priapism Diseases 0.000 description 1
230000008569 process Effects 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
GMVPRGQOIOIIMI-DWKJAMRDSA-N prostaglandin E1 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O GMVPRGQOIOIIMI-DWKJAMRDSA-N 0.000 description 1
238000011471 prostatectomy Methods 0.000 description 1
210000003689 pubic bone Anatomy 0.000 description 1
239000006215 rectal suppository Substances 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
230000004648 relaxation of smooth muscle Effects 0.000 description 1
229920005989 resin Polymers 0.000 description 1
239000011347 resin Substances 0.000 description 1
230000009329 sexual behaviour Effects 0.000 description 1
231100000872 sexual dysfunction Toxicity 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
235000012239 silicon dioxide Nutrition 0.000 description 1
229960001866 silicon dioxide Drugs 0.000 description 1
230000000392 somatic effect Effects 0.000 description 1
230000002269 spontaneous effect Effects 0.000 description 1
238000003860 storage Methods 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000000758 substrate Substances 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
206010042772 syncope Diseases 0.000 description 1
230000008337 systemic blood flow Effects 0.000 description 1
239000007916 tablet composition Substances 0.000 description 1
210000003478 temporal lobe Anatomy 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
238000004448 titration Methods 0.000 description 1
229940041597 tofranil Drugs 0.000 description 1
238000011200 topical administration Methods 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
210000003708 urethra Anatomy 0.000 description 1
210000004291 uterus Anatomy 0.000 description 1
230000004218 vascular function Effects 0.000 description 1
230000001714 vasocongestive effect Effects 0.000 description 1
230000024883 vasodilation Effects 0.000 description 1
230000000982 vasogenic effect Effects 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
229960000881 verapamil hydrochloride Drugs 0.000 description 1
230000008673 vomiting Effects 0.000 description 1
229940045860 white wax Drugs 0.000 description 1
229940090523 yocon Drugs 0.000 description 1
229960000949 yohimbine hydrochloride Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
Emergency Medicine (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Reproductive Health (AREA)
Endocrinology (AREA)
Gynecology & Obstetrics (AREA)
Urology & Nephrology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicinal Preparation (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Steroid Compounds (AREA)
Percussion Or Vibration Massage (AREA)
Control Of Fluid Pressure (AREA)
Medicines Containing Plant Substances (AREA)

NO19960549A 1993-08-13 1996-02-12 Anvendelse av et legemiddel med vasodilaterende aktivitet for fremstilling av et medikament for å forbedre seksualrespons hos etmenneske NO311785B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US10643493A	1993-08-13	1993-08-13
PCT/US1994/009048 WO1995005172A1 (en)	1993-08-13	1994-08-10	Methods for modulating the human sexual response

Publications (3)

Publication Number	Publication Date
NO960549D0 NO960549D0 (no)	1996-02-12
NO960549L NO960549L (no)	1996-04-12
NO311785B1 true NO311785B1 (no)	2002-01-28

Family

ID=22311403

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO19960549A NO311785B1 (no)	1993-08-13	1996-02-12	Anvendelse av et legemiddel med vasodilaterende aktivitet for fremstilling av et medikament for å forbedre seksualrespons hos etmenneske

Country Status (16)

Country	Link
US (1)	US5565466A (de)
EP (1)	EP0714300B1 (de)
JP (1)	JP3782101B2 (de)
KR (1)	KR100391025B1 (de)
CN (1)	CN1103589C (de)
AT (1)	ATE174795T1 (de)
BR (1)	BR9407250A (de)
CA (1)	CA2169071C (de)
DE (1)	DE69415535T2 (de)
DK (1)	DK0714300T3 (de)
ES (1)	ES2127409T3 (de)
GR (1)	GR3029500T3 (de)
NO (1)	NO311785B1 (de)
NZ (1)	NZ271567A (de)
WO (1)	WO1995005172A1 (de)
ZA (1)	ZA946123B (de)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5773457A (en) *	1995-02-15	1998-06-30	Cesar Roberto Dias Nahoum	Compositions
US6007836A (en) *	1993-05-28	1999-12-28	Vericade, Inc.	Transdermal vasodilator
GB9301192D0 (en)	1993-06-09	1993-06-09	Trott Francis W	Flower shaped mechanised table
US6143746A (en) *	1994-01-21	2000-11-07	Icos Corporation	Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use
US5731339A (en) *	1995-04-28	1998-03-24	Zonagen, Inc.	Methods and formulations for modulating the human sexual response
US5897880A (en)	1995-09-29	1999-04-27	Lam Pharmaceuticals, Llc.	Topical drug preparations
US6251436B1 (en)	1995-09-29	2001-06-26	L.A.M. Pharmaceutical Corporation	Drug preparations for treating sexual dysfunction
US6387407B1 (en)	1995-09-29	2002-05-14	L.A.M. Pharmaceutical Corporation	Topical drug preparations
US20020143007A1 (en) *	1996-02-02	2002-10-03	Garvey David S.	Nitrosated and nitrosylated alpha-adrenergic receptor antagonists, compositions and methods of use
US6294517B1 (en)	1996-02-02	2001-09-25	Nitromed, Inc.	Compositions and kits comprising alpha-adrenergic receptor antagonists and nitric oxide donors and methods of use
US5932538A (en) *	1996-02-02	1999-08-03	Nitromed, Inc.	Nitrosated and nitrosylated α-adrenergic receptor antagonist compounds, compositions and their uses
US5994294A (en) *	1996-02-02	1999-11-30	Nitromed, Inc.	Nitrosated and nitrosylated α-adrenergic receptor antagonist compounds, compositions and their uses
US6323211B1 (en)	1996-02-02	2001-11-27	Nitromed, Inc.	Compositions and methods for treating sexual dysfunctions
US20050065161A1 (en) *	1996-02-02	2005-03-24	Nitromed, Inc.	Nitrosated and nitrosylated alpha-adrenergic receptor antagonist compounds, compositions and their uses
US6469065B1 (en)	1996-02-02	2002-10-22	Nitromed, Inc.	Nitrosated and nitrosylated α-adrenergic receptor antagonist, compositions and methods of use
FR2748658B1 (fr) *	1996-05-15	2000-08-18	Biotec Centre Sa	Utilisation de composes du type "alpha-bloquants" notamment le moxisylyte et/ou ses derives pour le traitement de dysfonctionnements erectiles par voie transmucosale balanique
WO1998006333A1 (en) *	1996-08-09	1998-02-19	Urometrics, Inc.	Male impotence diagnostic ultrasound system
US6331543B1 (en) *	1996-11-01	2001-12-18	Nitromed, Inc.	Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use
US5958926A (en)	1996-11-01	1999-09-28	Nitromed, Inc.	Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
USRE37234E1 (en) *	1996-11-01	2001-06-19	Nitromed, Inc.	Nitrosated and nitrosylated phosphodiestrase inhibitor compounds, compositions and their uses
DE19646392A1 (de)	1996-11-11	1998-05-14	Lohmann Therapie Syst Lts	Zubereitung zur Anwendung in der Mundhöhle mit einer an der Schleimhaut haftklebenden, Pharmazeutika oder Kosmetika zur dosierten Abgabe enthaltenden Schicht
WO1998052569A1 (en) *	1997-05-19	1998-11-26	Zonagen, Inc.	Combination therapy for modulating the human sexual response
US20030004170A1 (en) *	1997-05-19	2003-01-02	Zonagen, Inc.	Combination therapy for modulating the human sexual response
EP1535611A3 (de) *	1997-06-23	2009-09-16	Strakan International Limited	Microdosistherapie von Gefässbedingten Erscheinungen durch NO-Donoren
CA2294480C (en)	1997-06-23	2008-05-20	Queen's University At Kingston	Microdose therapy of female sexual dysfunction by no, co, and their donors
FR2765483B1 (fr) *	1997-07-04	2000-02-04	Philippe Gorny	Medicament destine a traiter les dysfonctions erectiles
CA2295595A1 (en)	1997-07-09	1999-01-21	Androsolutions, Inc.	Improved methods and compositions for treating male erectile dysfunction
US6103765A (en)	1997-07-09	2000-08-15	Androsolutions, Inc.	Methods for treating male erectile dysfunction
US6251076B1 (en)	1997-08-01	2001-06-26	Urometrics Inc.	Male impotence diagnostic ultrasound system
US5947901A (en)	1997-09-09	1999-09-07	Redano; Richard T.	Method for hemodynamic stimulation and monitoring
US5879665A (en) *	1997-09-25	1999-03-09	The Board Of Regents Of The University Of Oklahoma	Composition for causing skin lightening
US6110448A (en) *	1997-09-25	2000-08-29	The Board Of Regents Of The University Of Oklahoma	Method for causing skin lightening
US5919436A (en) *	1997-09-25	1999-07-06	The Board Of Regents Of The University Of Oklahoma	Method of lightening skin
GB9720797D0 (en) *	1997-09-30	1997-12-03	Rhodes John	Pharmaceutical composition for the treatment of inflammatory bowel disease and irritable bowel syndrome
US6593369B2 (en)	1997-10-20	2003-07-15	Vivus, Inc.	Methods, compositions, and kits for enhancing female sexual desire and responsiveness
US5877216A (en) *	1997-10-28	1999-03-02	Vivus, Incorporated	Treatment of female sexual dysfunction
US20050070516A1 (en) *	1997-10-28	2005-03-31	Vivus Inc.	As-needed administration of an androgenic agent to enhance female desire and responsiveness
AU740758B2 (en) *	1997-10-28	2001-11-15	Vivus, Inc.	Treatment of female sexual dysfunction
US20040044080A1 (en) *	1997-10-28	2004-03-04	Place Virgil A.	Treatment of dyspareunia with topically administered nitroglycerin formulations
US6548490B1 (en)	1997-10-28	2003-04-15	Vivus, Inc.	Transmucosal administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
AUPP010397A0 (en) *	1997-10-30	1997-11-20	Vaisman, Jakov	Method and composition for treatment of sexual dysfunction
US6472425B1 (en) *	1997-10-31	2002-10-29	Nitromed, Inc.	Methods for treating female sexual dysfunctions
AU2318599A (en)	1998-01-13	1999-08-02	Urometrics, Inc.	Devices and methods for monitoring female arousal
US5945117A (en) *	1998-01-30	1999-08-31	Pentech Pharmaceuticals, Inc.	Treatment of female sexual dysfunction
GB9802078D0 (en) *	1998-01-30	1998-03-25	Futura Medical Limited	Preparation for treatment of erectile dysfunction
FR2774593B1 (fr) *	1998-02-12	2000-05-05	Philippe Gorny	Obtention d'un medicament destine a combattre les dysfonctions sexuelles feminines
FR2774594A1 (fr) *	1998-02-12	1999-08-13	Philippe Gorny	Medicament destine notamment a prevenir ou traiter les dysfonctions erectiles
US6124461A (en) *	1998-05-26	2000-09-26	Saint Louis University, Health Services Center, Research Administration	Compounds, compositions, and methods for treating erectile dysfunction
US6365590B1 (en)	1998-05-26	2002-04-02	Saint Louis University	Compounds, compositions and methods for treating erectile dysfunction
US5942545A (en) *	1998-06-15	1999-08-24	Macrochem Corporation	Composition and method for treating penile erectile dysfunction
TWI223598B (en) *	1998-06-22	2004-11-11	Pfizer Ireland Pharmaceuticals	An intranasal pharmaceutical composition for the treatment of male erectile dysfunction or female sexual disorders, an intranasal delivery system or device and sildenafil mesylate
EP1235563A2 (de) *	1998-08-26	2002-09-04	Queen's University At Kingston	Verwendung von drucksenkenden mitteln zur gefaessremodulierung bei genitaldysfunktion
US6482426B1 (en) *	1998-09-17	2002-11-19	Zonagen, Inc.	Compositions for the treatment of male erectile dysfunction
US6825234B2 (en)	1998-12-10	2004-11-30	Nexmed (Holdings) , Inc.	Compositions and methods for amelioration of human female sexual dysfunction
US6486207B2 (en) *	1998-12-10	2002-11-26	Nexmed (Holdings), Inc.	Compositions and methods for amelioration of human female sexual dysfunction
US6455564B1 (en) *	1999-01-06	2002-09-24	Pharmacia & Upjohn Company	Method of treating sexual disturbances
EP1220666A2 (de) *	1999-04-06	2002-07-10	Zonagen, Inc.	Methoden zur modulierung der menschlichen sexualansprechlichkeit
US6214849B1 (en)	1999-04-29	2001-04-10	Lupin Laboratories Limited	Use of nicorandil in treatment of sexual dysfunction or for enhancement of sexual function in mammals including humans
IT1312310B1 (it)	1999-05-07	2002-04-15	Recordati Ind Chimica E Farma	Uso di antagonisti selettivi del recettore adrenergico a 1b per ilmiglioramento della disfunzione sessuale
US6405219B2 (en)	1999-06-22	2002-06-11	F5 Networks, Inc.	Method and system for automatically updating the version of a set of files stored on content servers
US6730691B1 (en)	2000-02-10	2004-05-04	Miles A. Galin	Uses of alpha adrenergic blocking agents
AU6124401A (en) *	2000-05-09	2001-11-20	Nitromed Inc	Infrared thermography and methods of use
US20040137081A1 (en) *	2003-01-13	2004-07-15	Peter Rohdewald	Attaining sexual wellness and health of the sexual vascular system with proanthocyanidins
ATE369868T1 (de) *	2000-06-27	2007-09-15	Qualilife Pharmaceuticals Inc	Zusammensetzungen und verfahren zur behandlung der weiblichen sexuellen reaktion
FI20002755A0 (fi) *	2000-12-15	2000-12-15	Orion Yhtymae Oyj	Menetelmä erektiilin dysfunktion hoitamiseen
US20020107230A1 (en) *	2000-12-22	2002-08-08	Waldon R. Forrest	Methods and formulations for the treatment of female sexual dysfunction
CA2435546A1 (en) *	2001-02-08	2002-08-15	Alice C. Martino	Rapid-onset medicament for the treatment of sexual dysfunction
WO2002069906A2 (en)	2001-03-06	2002-09-12	Cellegy Pharmaceuticals, Inc.	Compounds and methods for the treatment of urogenital disorders
US20020172712A1 (en) *	2001-03-19	2002-11-21	Alan Drizen	Antiemetic, anti-motion sustained release drug delivery system
US20030138494A1 (en) *	2001-05-15	2003-07-24	L.A.M. Pharmaceutical Corporation	Drug preparations for treating sexual dysfunction
US20030158184A1 (en) *	2001-12-21	2003-08-21	Garvey David S.	Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
CN101027061B (zh)	2004-05-11	2014-03-12	情感智能有限责任公司	药物制剂及其在治疗女性性功能障碍中的应用
EP1790343A1 (de)	2005-11-11	2007-05-30	Emotional Brain B.V.	Pharmazeutische Zusammensetzungen und deren Verwendung zur Behandlung sexueller Störungen der Frau
EP1925307A1 (de)	2006-11-03	2008-05-28	Emotional Brain B.V.	Verwendung von 3-alpha-androstanediol zur Behandlung sexueller Dysfunktion
US8852082B2 (en) *	2008-10-10	2014-10-07	Peter Forsell	Stimulation of penis erection
US8939889B1 (en)	2013-08-22	2015-01-27	Coloplast A/S	Pump bulb for an implantable penile prosthetic
US20170354331A1 (en) *	2014-11-17	2017-12-14	Rochester Institute Of Technology	Blood Pressure and Arterial Compliance Estimation from Arterial Segments

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3943246A (en) *	1972-07-10	1976-03-09	Sandoz Ltd.	Organic compounds
US4139617A (en) *	1974-05-13	1979-02-13	Richardson-Merrell Inc.	19-Oxygenated-androst-5-enes for the enhancement of libido
US4127118B1 (en) *	1977-03-16	1995-12-19	Alvaro Latorre	Method of effecting and enhancing an erection
US4530920A (en) *	1983-11-07	1985-07-23	Syntex (U.S.A.) Inc.	Nonapeptide and decapeptide analogs of LHRH, useful as LHRH agonist
US4885173A (en) *	1985-05-01	1989-12-05	University Of Utah	Methods and compositions for noninvasive dose-to-effect administration of drugs with cardiovascular or renal vascular activities
US4863911A (en) *	1986-08-04	1989-09-05	University Of Florida	Method for treating male sexual dysfunction
US4801587A (en) *	1987-03-02	1989-01-31	Gene Voss	Impotence ointment
US5256652A (en) *	1987-11-12	1993-10-26	Pharmedic Co.	Topical compositions and methods for treatment of male impotence
SE463851B (sv) *	1988-09-02	1991-02-04	Amsu Ltd	Komposition foer behandling av erektil dysfunktion via uretra
US5059603A (en) *	1989-06-12	1991-10-22	Centuries Laboratories, Inc.	Method and composition for treating impotence
US5065744A (en) *	1989-06-16	1991-11-19	Zusmanovsky Zinovy A	Device for treatment of sexual impotence in human males
FR2649613B1 (fr) *	1989-07-11	1991-09-27	Virag Ronald	Medicament vaso-actif
US5236904A (en) *	1989-09-18	1993-08-17	Senetek, Plc	Erection-inducing methods and compositions
US5270323A (en) *	1990-05-31	1993-12-14	Pfizer Inc.	Method of treating impotence
US5399581A (en) *	1990-12-26	1995-03-21	Laragh; John H.	Method and compositions for treatment of sexual impotence

1994
- 1994-08-09 US US08/286,615 patent/US5565466A/en not_active Expired - Lifetime
- 1994-08-10 BR BR9407250A patent/BR9407250A/pt not_active Application Discontinuation
- 1994-08-10 KR KR1019960700714A patent/KR100391025B1/ko not_active Expired - Lifetime
- 1994-08-10 AT AT94925240T patent/ATE174795T1/de not_active IP Right Cessation
- 1994-08-10 ES ES94925240T patent/ES2127409T3/es not_active Expired - Lifetime
- 1994-08-10 WO PCT/US1994/009048 patent/WO1995005172A1/en not_active Ceased
- 1994-08-10 CN CN94193071A patent/CN1103589C/zh not_active Expired - Fee Related
- 1994-08-10 JP JP50706195A patent/JP3782101B2/ja not_active Expired - Lifetime
- 1994-08-10 DK DK94925240T patent/DK0714300T3/da active
- 1994-08-10 EP EP94925240A patent/EP0714300B1/de not_active Expired - Lifetime
- 1994-08-10 NZ NZ271567A patent/NZ271567A/en not_active IP Right Cessation
- 1994-08-10 CA CA002169071A patent/CA2169071C/en not_active Expired - Lifetime
- 1994-08-10 DE DE69415535T patent/DE69415535T2/de not_active Expired - Fee Related
- 1994-08-15 ZA ZA946123A patent/ZA946123B/xx unknown
1996
- 1996-02-12 NO NO19960549A patent/NO311785B1/no not_active IP Right Cessation
1999
- 1999-02-26 GR GR990400597T patent/GR3029500T3/el unknown

Also Published As

Publication number	Publication date
EP0714300A4 (de)	1996-07-24
ZA946123B (en)	1995-03-20
KR960703588A (ko)	1996-08-31
DE69415535T2 (de)	1999-06-17
ATE174795T1 (de)	1999-01-15
JPH09501677A (ja)	1997-02-18
NO960549D0 (no)	1996-02-12
CA2169071C (en)	2008-10-21
AU696815B2 (en)	1998-09-17
KR100391025B1 (ko)	2003-10-04
EP0714300A1 (de)	1996-06-05
CA2169071A1 (en)	1995-02-23
DE69415535D1 (de)	1999-02-04
WO1995005172A1 (en)	1995-02-23
EP0714300B1 (de)	1998-12-23
BR9407250A (pt)	1996-09-24
US5565466A (en)	1996-10-15
JP3782101B2 (ja)	2006-06-07
GR3029500T3 (en)	1999-05-28
NZ271567A (en)	1997-12-19
DK0714300T3 (da)	1999-08-23
AU7523894A (en)	1995-03-14
ES2127409T3 (es)	1999-04-16
CN1128950A (zh)	1996-08-14
NO960549L (no)	1996-04-12
CN1103589C (zh)	2003-03-26

Legal Events

Date	Code	Title	Description
2010-03-22	MM1K	Lapsed by not paying the annual fees

Publication	Publication Date	Title
US5565466A (en)	1996-10-15	Methods for modulating the human sexual response
EP0767660B1 (de)	1999-10-20	Verfahren und formulierungen zur modulation der sexualreaktion beim menschen
US20230255940A1 (en)	2023-08-17	Oxymetazoline for the treatment of ano-rectal disorders
NO322079B1 (no)	2006-08-14	Blanding som omfatter en alfa-adrenerg antagonist og en dopaminerg agonist.
AU696815C (en)	1999-06-24	Methods for modulating the human sexual response
AU723242B2 (en)	2000-08-24	Methods for modulating the human sexual response
WO2000059491A2 (en)	2000-10-12	Methods for modulating the human sexual response
Anglade et al.	2004	Male sexual dysfunction
HK1028197B (en)	2007-04-13	Combination therapy for modulating the human sexual response
Ratnasooriya	1978	Effects of sympathomimetic drugs on the contractility of the vas deferens and on fertility in the male rat and rabbit